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ABSTRACT 27 
Background: There is a need to measure antibiotic resistance of Pseudomonas aeruginosa 28 
(PA) in cystic fibrosis (CF), either qualitatively or quantitatively, to inform patient 29 
management. The aim of this study was to develop a simple method by which resistance can 30 
be quantified by calculating a relative resistance index (RRI), and to assess correlation of 31 
RRIs with clinical variables. 32 
Methods: In our model, RRIs were calculated based on resistance to aztreonam, ceftazidime, 33 
ciprofloxacin, colistin, meropenem, tazocin, temicillin and tobramycin.  Eighty-five adults 34 
with CF and chronic PA colonisation were identified. For each, all PA cultures were allocated 35 
a score of 0 for susceptible, 0.5 for intermediate resistance or 1 for resistant for each 36 
antibiotic listed above, and the RRI calculated by dividing the sum of these by the number of 37 
antibiotics, giving a maximum score of 1. The mean RRIs for all cultures were correlated 38 
with key clinical variables monitored in cystic fibrosis patients (including age, FEV1, IV 39 
antibiotic days and BMI). 40 
Results: RRIs for non-mucoid PA exhibited moderate positive correlation with total number 41 
of IV days (r=0.405; p<0.001) and moderate negative correlation with FEV1 % predicted 42 
(r=−0.437; p<0.001).  RRIs were not significantly correlated with duration of colonisation, 43 
typing (clonal vs other strain) or BMI.  Median RRIs were significantly higher for females 44 
(0.26, IQR 0.13 – 0.54) than males (0.18, IQR 0.07 – 0.37) for non-mucoid PA only (p = 45 
0.03).   46 
Conclusions: RRI is an easily calculated measure that correlates with other clinical variables 47 
in cystic fibrosis patients and enables quantitative monitoring of resistance. 48 
49 
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INTRODUCTION 50 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder characterised by defective 51 
mucociliary clearance and chronic airway infection [1].  The most commonly isolated 52 
pathogen from CF airways is the opportunistic Gram-negative bacterium Pseudomonas 53 
aeruginosa (PA) [2].  Chronic PA infection is associated with significant morbidity and 54 
mortality in CF patients [3] and necessitates multiple antibiotic courses, which increase the 55 
risk of the development of antibiotic resistance [2].  Many of the PA strains isolated from CF 56 
airways are of the mucoid phenotype, capable of producing large quantities of alginate which 57 
enable the formation of a matrix in which microcolonies can exist.  These microcolonies are 58 
thought to provide protection against the host immune response and antibiotic therapy; 59 
conversion of PA through mutation in patients to the mucoid phenotype is associated with 60 
increased morbidity and mortality [4]. Typically, initial colonisation is with non-mucoid 61 
forms of PA, with the mucoid form predominate later.  62 
 63 
Antibiotic resistance in PA may be driven by inappropriate use of antibiotics in either oral, 64 
nebulised or intravenous formulations, as well as by the use of biocides which might also 65 
drive increased antibiotic resistance [5].  Development of novel virulence model systems in 66 
PA may help predict clinical outcomes in patients with CF [6]. 67 
 68 
There is a need to measure antibiotic susceptibility (AS) of PA, either qualitatively or 69 
quantitatively, to inform patient management.  AS in PA is generally reported by classifying 70 
resistance to individual antibiotics qualitatively (sensitive (S), intermediate (I) or resistant 71 
(R)) or quantitatively (minimum inhibitory concentration (MIC)).  PA strains can thus be 72 
grouped by the presence or absence of multi-drug resistance, the definition of which varies 73 
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considerably in biomedical literature [7].  Multiple-antibiotic resistant PA has previously 74 
been associated with a lower FEV1 % predicted [8].  75 
 76 
The aim of this study was to develop a method by which antibiotic resistance in PA can be 77 
quantified by calculating a relative resistance index (RRI).  This would provide a measure of 78 
the total antibiotic resistance of an organism at a given time point, using multiple antibiotic 79 
classes (and multiple agents within each of those classes). The RRI would also allow tracking 80 
of changes in AS over time. To determine the potential clinical relevance e of the RRI, 81 
correlation with important clinical variables in cystic fibrosis patients, including FEV1 % 82 
predicted, number of IV (intravenous) antibiotic days and BMI (body mass index) were 83 
assessed.  84 
 85 
  86 
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MATERIALS AND METHODS 87 
Patients attending the Regional Adult Cystic Fibrosis Centre in Northern Ireland (NI) were 88 
identified who met the Leeds definition [9] for chronic colonisation with PA between 2010 89 
and 2011.  PA was isolated from CF patients’ fresh expectorated sputum in a UKAS 90 
accredited NHS Clinical Microbiology laboratory, in accordance with laboratory 91 
methodologies, as defined in the UK CF Trust guidelines [Laboratory Standards for 92 
Processing Microbiological Samples from People with Cystic Fibrosis] [10].Patients 93 
concomitantly colonised with Burkholderia cepacia complex were excluded from the 94 
analysis.  For each patient, the following information was obtained from laboratory data and 95 
the Northern Ireland Port CF registry: date of birth, date of first culture of PA, date first 96 
defined as chronic PA (Leeds definition), FEV1 % predicted at annual review 2011, BMI at 97 
annual review 2011, total number of IV antibiotic days for 2010 and 2011.  Annual review 98 
values were used instead of other hospital encounters as these were felt to provide values that 99 
were more reflective of the patients’ baselines and less likely to be influenced by pulmonary 100 
exacerbations.  Patients were also classified as to whether they cultured a distinct clonal type 101 
commonly isolated in NI, as defined by service genotyping analysis performed by Public 102 
Health England, or another unique genotype strain of PA.  103 
Patients with CF, especially those from whom organisms are persistently isolated, are seen 104 
often at the clinic and sputum is sent to the laboratory at every visit.  Antibiotic sensitivities, 105 
normally performed on one mucoid and one non-mucoid isolate per calendar month, were 106 
estimated using the disc method.  For each antibiotic, a report of sensitive (S), intermediate 107 
resistance (I) or resistant (R) was issued.  During the study period 2010 to 2011, Clinical and 108 
Laboratory Standards Institute (CLSI) zone size criteria were applied [11]  109 
For each patient, all cultures of PA for which antibiotic sensitivity data was available during 110 
the study period (2010 – 2011) were allocated a score of 0 for susceptible, 0.5 for 111 
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intermediate resistance or 1 for resistant for each of the antibiotics listed above. An overall 112 
RRI was calculated by adding the means scores for each antibiotic together and dividing by 113 
the number of antibiotics (eight in our analysis), giving a minimum RRI of 0 (fully sensitive) 114 
and a maximum RRI of 1 (pan-resistant).  For the purpose of the study, for each patient we 115 
used the mean value of all cultures over the two-year period, to maximise data utilisation and 116 
provide a summary measure of resistance over the two-year period.  117 
All statistical analyses were performed using SPSS v. 19.0 (IBM Corp., Armonk, NY, USA). 118 
Differences between median RRIs between 2010 and 2011 were assessed using Wilcoxon 119 
signed rank test. Differences in median RRIs between i) mucoid and non-mucoid PA cultures 120 
ii) strain type (LES [Liverpool Epidemic Strain] or unique strain) and iii) gender were 121 
assessed using the Mann-Whitney test. Correlation of RRIs with clinical variables (age, 122 
duration of chronic PA colonisation, number of IV days 2010-2011, FEV1 % predicted and 123 
BMI at annual review 2011) was assessed using Spearman’s Rank correlation.   124 
 125 
 126 
  127 
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RESULTS  128 
Eighty-five patients met the inclusion criteria.  As illustrated in Figure 1, the median RRIs 129 
were significantly higher for non-mucoid (0.24, IQR 0.10 – 0.43) than mucoid (0.06, IQR 130 
0.01 – 0.13) PA (p < 0.001). Median RRIs did not differ significantly between 2010 and 2011 131 
for non-mucoid (p = 0.14) or mucoid PA (p = 0.87). Median RRIs were significantly higher 132 
for females (0.26, IQR 0.13 – 0.54) than males (0.18, IQR 0.07 – 0.37) for non-mucoid PA 133 
only (p = 0.03).  ).  There was no significant difference between median RRIs in those 134 
identified as having the distinct clonal type compared to those with unique PA strains for 135 
non-mucoid (p = 0.14) or mucoid PA (p = 0.55). In patients with the aforementioned clonal 136 
type, RRIs ranged from 0.00 to 0.75.  137 
 138 
There was a moderate positive correlation of RRIs with age and number of IV days for non-139 
mucoid PA, as detailed in Table 1(A) and (B), whilst in comparison, this was not case for 140 
mucoid strains. Figure 2 shows a scatterplot of mean relative resistance indices over time 141 
period 2010-2011 against FEV1 % predicted at annual review 2011. RRI was not significantly 142 
correlated with duration of colonisation with chronic PA, typing (clonal vs other strain) or 143 
BMI. RRIs for mucoid PA did not correlate significantly with any of the clinical variables 144 
examined.  145 
 146 
Table 1 (C) depicts the correlation of resistance scores for individual antibiotics in non-147 
mucoid PA against FEV1 % predicted and number of IV antibiotic days.Resistance to 148 
meropenem had the strongest negative correlation with FEV1 % predicted (r = -0.52, p < 149 
0.001), followed by ceftazidime (-0.44, p < 0.001). Resistance to ceftazidime had the 150 
strongest positive correlation with number of IV antibiotic days (0.42, p < 0.001), followed 151 
by meropenem (0.41, <0.001). Although overall scores for mucoid PA did not correlate with 152 
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FEV1 % predicted, significant negative correlation was observed with the score for 153 
ceftazidime, meropenem, tazocin and tobramycin in mucoid PA, the strongest and most 154 
significant being for tobramycin (-0.37, p = 0.003), followed by meropenem (-0.31, p = 155 
0.017).  156 
 157 
158 
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DISCUSSION 159 
 160 
Chronic infections behave very differently.  Although AS is widely used in treating acute 161 
infections, there have been few attempts to develop algorithms in CF and elsewhere, which 162 
define AS in terms of (i) the totality of antibiotic resistance of an organism at a given time 163 
point, over multiple classes/agents within each class or (ii) the change in AS over time 164 
reflecting an evolving resistome of PA.  But what metrics are optimal for fulfilment of these 165 
criteria of such a novel marker/index?  In our RRI model, we have proposed the equal 166 
weighting of AS across eight antibiotic agents from four antibiotic classes  167 
 168 
Correlation with clinical parameters were as follows. As expected, RRIs were higher for non-169 
mucoid PA, as strains with mucoid phenotype are protected from the selective pressure 170 
imposed by antibiotics.  Consequently, it seemed appropriate to analyse correlation with 171 
clinical variables separately for mucoid and non-mucoid PA.  Our findings show that RRI for 172 
PA displays significant correlation with other clinical variables in CF, especially for non-173 
mucoid PA.  Total RRIs (i.e. against all antibiotics tested) were positively correlated with 174 
number of IV antibiotic days. Figure 2 shows the relationship when RRI is plotted against 175 
FEV1 values.  It should be noted that from these data, we cannot state that poorer lung 176 
function is caused by increasing RRI values and consequently this is not a cause and effect 177 
relationship.  We are not proposing that RRI is a predictor or cause of lung function, but that 178 
the two show a moderate association, most likely due to those with poorer lung function 179 
requiring more antibiotic therapy which in turn drives antibiotic resistance, with a resulting 180 
increase in RRI values. One surprising finding was the lack of an association between 181 
duration of chronic PA colonisation and RRIs, with the number of IV antibiotics days 182 
appearing to be a more important contributor to resistance than duration.  Median RRIs were 183 
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higher for females than males. This is unsurprising as female patients had more IV antibiotic 184 
days, which is likely to have driven antibiotic resistance.  Although not recorded in our study, 185 
females are also likely to have received more intensive nebulised and oral antibiotic therapy, 186 
due to the observation that females tend to experience earlier PA infection and poorer 187 
outcomes [12].  RRIs did not differ significantly between patients with the clonal strain 188 
compared to those with unique strains, and there was a wide range of RRIs within those with 189 
the clonal strain, suggesting considerable heterogeneity in its resistome.  190 
 191 
 192 
As regards resistance to individual antibiotics, when scores for individual antibiotic resistance 193 
are analysed, it appears that meropenem resistance is most strongly associated with a lower 194 
FEV1, followed by ceftazidime.  The reason for the strong association of meropenem 195 
resistance with adverse FEV1 % predicted is unclear; however it is most likely that this is a 196 
reflection of meropenem being reserved for more unwell individuals who may have a lower 197 
FEV1 % predicted, leading to these individuals developing greater meropenem resistance.  198 
This relationship requires further understanding and is currently being investigated.  As 199 
carbapenem resistance is a particularly concerning finding, it may be pertinent to consider 200 
weighting meropenem resistance more highly in future RRI models.   201 
 202 
alternative indices could be adopted, such as RRI3/3 or RRI6/12, which may yield higher 203 
quality information for targeted questions, and tailored accordingly in terms of its design, 204 
depending on what information is required.  .  Measurement of the gradient of the linear line 205 
of best fit, would give an indication of the rate of change in AS (ΔAS), which is driven by 206 
acquisition of antibiotic resistance and related antibiotic resistance mutation frequency, thus 207 
the higher the ΔAS value, the faster the development of resistance.  Such a marker could be 208 
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extrapolated to potentially estimate future antibiotic resistance development and thus chart 209 
certain windows of opportunity, for example, escalation of treatment.   210 
 211 
Overall, it is probable that individuals with lower FEV1% predicted, who may be more 212 
unwell, require more IV days and therefore develop more resistant forms of PA.  However, it 213 
is should also be considered that more resistant strains of PA may be predictive of poorer 214 
outcomes. Regardless, it appears that greater antibiotic resistance is a marker of lower FEV1 215 
% predicted.  In a study of over 4000 CF patients, Ren et al [8] found that mean FEV1 216 
decline did not change significantly after Multiple antibiotic-resistant Pseudomonas 217 
aeruginosa (MARPA) detection. Consequently they perceived that multi-antibiotic resistance 218 
was marker of severe disease, but did not in itself contribute to more rapid decline in FEV1. 219 
 220 
In summary, the advantages of objectively and quantitatively examining AS over time via the 221 
RRI marker, within the context of chronic PA colonisation include the ability to (i) succinctly 222 
define with a single value how resistant an organism is in its entirety over several classes of 223 
antibiotics, at a given time point.  Such information would be useful to clinicians in helping 224 
to determine suitable antibiotic management strategies, e.g antibiotic cycling, (ii) monitor the 225 
rate at which antibiotic resistance is developing, (iii) provide evidence relating to the 226 
introduction/elimination of particular strains of PA, as seen with markedly different RRI 227 
scores appearing/disappearing, with implications for infection control/antibiotic management,  228 
A rapidly changing RRI could also indicate the need to re-type the PA to assess if a new 229 
strain has been introduced.  This could provide guidance as to when typing is warranted, as 230 
most centres do not regularly type PA due to financial restraints, and (iv) estimate windows 231 
of opportunity where antibiotic resistance is important e.g. deteriorating lung health and 232 
antibiotic allergy. 233 
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 234 
This work represents an advance in biomedical science because to date, no such cumulative 235 
approach has been described.  This novel Relative Resistance Index (RRI) marker may be a 236 
useful tool in forming a cumulative determination of antimicrobial susceptibility over several 237 
antibiotics through time, with useful benefits in quantifying antimicrobial resistance to 238 
clinicians and other healthcare professionals. 239 
 240 
 241 
What is known about this subject: 242 
 243 
 Antimicrobial resistance has now emerged as a major threat to public health at a 244 
national and international level 245 
 246 
 Routine clinical microbiology laboratories test antimicrobial resistance individually 247 
for each antibiotic  248 
 249 
 There is no laboratory biomarker or algorithm that attempts to link cumulative 250 
antimicrobial susceptibility for several antibiotics simultaneously into a single holistic 251 
marker, for ease of interpretation amongst clinical staff 252 
 253 
 254 
What this paper adds: 255 
 256 
 The proposed Relative Resistance Index (RRI) is a means of combining single 257 
antimicrobial susceptibilities into a single index, that is easily interpreted by clinical 258 
staff 259 
 260 
 RRI provides a flexible and quantitative measure of resistance which allows statistical 261 
correlation of resistance with other clinical variables. In the patients in our study, RRI 262 
showed a moderate association with lung function and number of IV antibiotic days.  263 
 264 
 Within cystic fibrosis (CF), where antimicrobial resistance has a major influence on 265 
patient morbidity and mortality, the RRI could be extrapolated to potentially estimate 266 
future antibiotic resistance development and thus chart certain clinical windows of 267 
opportunity, for example, escalation of treatment.   268 
 269 
  270 
 271 
  272 
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Figure 1. Box plot of mean relative resistance indices for non-mucoid compared with mucoid 320 
Pseudomonas aeruginosa for cultures taken over 2010-2011. 321 
 322 
 323 
 324 
 325 
326 
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Figure 2:  Scatterplot of mean relative resistance indices over time period 2010-2011 327 
against FEV1 % predicted at annual review 2011. 328 
 329 
 330 
 331  332 
 333 
 334 
 335 
  336 
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Table 1.   337 
 338 
A. Correlation between relative resistance indices (mean over 2010 and 2011) and clinical 339 
variables for non-mucoid and mucoid Pseudomonas aeruginosa. For non-mucoid PA, relative 340 
resistance index correlates positively with age and number of intravenous antibiotic days, and 341 
negatively with FEV1 % predicted.   342 
 343 
 Spearman’s Rank Correlation – Correlation Coefficient (Sig. 2 tailed) 
 
 Non-mucoid PA  
RRI 2010-2011 
 
Mucoid PA  
RRI 2010 – 2011 
Age 0.24 (0.04)* 0.036 (0.77) 
Duration of Chronic PA 
colonisation 
0.06 (0.62) 0.090 (0.47) 
Number of IV antibiotic days 
2010 – 2011 
0.41 (<0.001)** 0.122 (0.33) 
FEV1 % predicted 2011 
(annual review) 
-0.44 (<0.001)** -0.014 (0.91) 
BMI 2011 (annual review) 
 
-0.09 (0.46) 
 
-0.081 (0.53) 
 
 
 344 
B. Multiple linear regression model for predicting mean relative resistance index for non-mucoid 345 
Pseudomonas aeruginosa in 2011. 346 
 347 
 Unstandardized 
co-efficient (B) 
t test statistic for 
co-efficient 
Significance  
Gender  0.960 1.850 0.072 
Age 0.063 1.823 0.076 
Typing (clonal strain or other) -0.694 -1.304 0.200 
Duration of chronic PA colonisation 0.000 0.687 0.496 
Total IV days 2010-2011 0.018 2.393 0.021* 
 
 348 
C. Correlation between resistance scores for individual antibiotics and FEV1 % predicted 349 
2011 and total intravenous antibiotic days 2010 – 2011.   350 
 351 
  Spearmans Rank Correlation – Correlation 
Coefficient (Sig. 2 tailed) 
  FEV1 % predicted 2011 Total IV antibiotic days 
2010 – 2011 
 
 
 
 
Resistance score for 
individual antibiotics 
Non-mucoid PA 2010-2011 
Aztreonam  -0.27 (0.02)* 0.35 (0.001)** 
Ceftazidime  -0.44 (<0.001)** 0.428 (<0.001)** 
Ciprofloxacin  -0.13 (0.298) 0.14 (0.21) 
Colistin  -0.16 (0.196) 0.09 (0.41) 
Meropenem  -0.52 (<0.001)** 0.41 (<0.001)** 
Tazocin  -0.367 (0.001)** 0.41 (<0.001)** 
Temicillin  -0.20 (0.10) 0.29 (0.011)* 
Tobramycin  -0.42 (<0.001)** 0.258 (0.03)* 
 
  352 
